Neuropace (NPCE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Neuropace (NPCE) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.28 of bullish evidence against -0.29 bearish.

Neuropace last closed at $13.22, +4.09% on the session.

Against the IVW growth benchmark the position is +3.17% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

4 graded predictions for NPCE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Neuropace in the 9th percentile on return on equity, where 100 is best.

Neuropace is classified under Health Care / Health Care Equipment & Supplies, with a market capitalisation of $435.91M.

StockMap tracks Neuropace as the 77th largest of the 133 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.

Across that group the current two-week reads are 67 Neutral, 61 Moderate Underperform, 4 Strong Underperform and 1 Moderate Outperform.

On that composite Neuropace ranks 73rd of 133 in the group, against a group median of -0.21.